On the stock market since 2021, it operates in the world of health and science. It has 223 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 44% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 36% a year on average.
Sales run at $56.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 31 buys and 14 sells. Management buying with its own money is usually read as a good sign.
A loss of $53.3M against $56.7M in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, CVRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CVRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (12/100) says the stock isn’t cheap.